A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 669 participants.
Also called NCT05443594
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 669 participants
- Sponsor
- Registry
-
NCT05443594
-
- Other papers using this trial's data
- Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2
- Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05443594. Non-randomized; no masking; primary purpose treatment. Start 2023-02-28 (actual); primary completion 2025-02-11 (actual). Results posted on 2025-10-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
- Acronym
- ADVANTAGE AF
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- Phase 1: FARAPULSE Ablation System
- Intervention (Device)
- Phase 2: FARAPULSE Ablation System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct05443594- Content hash
3045de27edbb9d61a4756391ba415c9a0363dfc6d78f0ca0238f2a55ac688285